Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA national ad campaign

Executive Summary

Board of directors authorizes 1995 campaign at its Dec. 8 meeting in New York City. The fourth year of the campaign will feature "HealthMatters" booklets on steps to prevent or detect diseases and on research into potential therapeutics. The first three specific diseases to be addressed are heart attacks, breast cancer and stroke: the heart attack booklet is scheduled for release in February. The booklets will be distributed, in part, as inserts in Newsweek, Reader's Digest and Time, with ads about the booklets in U.S. News, Smithsonian, Scientific American, The New York Times Magazine and New Yorker. TV ads announcing the availability of the brochures will appear on CNN and other national cable networks, PhRMA says. The board also votes to continue the "Inside the Beltway" (Washington, D.C. area) newspaper issues ads, which have been appearing since 1988. La Neil Gregory has been promoted to VP-advertising to head the advertising effort

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS025453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel